Report forecast the global lysosomal
storage diseases market to grow at a CAGR of 7.43% during the period 2017-2021.
Lysosomal storage diseases (LSDs) refer to
a group of diseases arising because of the deficiency of lysosomal enzymes,
which leads to the accumulation of partially digested or undigested
macromolecules inside the cell. LSDs includes progressive diseases with
variable ages of onset and clinical symptoms. LSDs are autosomal recessive
disorders that are passed on from generation to generation. However, Fabry
disease and MPS II are X-linked recessive disorders, which are inherited
through mutated alleles on X chromosome.
The report covers the present scenario and
the growth prospects of the global lysosomal storage diseases market for
2017-2021. The report presents a detailed picture of the market by way of
study, synthesis, and summation of data from multiple sources.
The
market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA
According to the report, one driver in the
market is unmet medical needs. The need for efficacious therapeutics that can
either slow or reverse the progression of disease is on the rise in the market.
The therapeutic options available to treat LSDs is very limited, especially in
particular disease subsets such as Gaucher disease type II. The inability of
the available treatments to improve neurological symptoms associated with LSDs
because of the limited penetration of blood brain barrier (BBB) by ERTs also
represent a high unmet need for this disease. For instance, there is a lack of
safe treatment options for early stages of Pompe disease.
Further, the report states that one
challenge in the market is expensive treatment regimen for LSDs. The increasing
cost of drugs has been a concern in the global LSDs market. The need for a
cost-effective therapy to treat these disease, especially in developing
countries is on the rise. The treatment of LSDs requires life-long
administration of drugs, as it may lead to non-compliance in individuals and
withdrawal from treatment regimens resulting in decreased consumption of
medicines. The rise in cost of these drugs is due to lack of competition and
low density of drugs marketed for the treatment of same indication.
Global
Lysosomal Storage Diseases Market 2017-2021, has
been prepared based on an in-depth market analysis with inputs from industry
experts. The report covers the market landscape and its growth prospects over
the coming years. The report also includes a discussion of the key vendors
operating in this market.
key players in the global lysosomal storage
diseases market: Actelion Pharmaceuticals, BioMarin, Genzyme, and Shire.
Other Prominent Vendors in the market are:
Alexion Pharmaceuticals, Amicus Therapeutics, Chiesi Farmaceutici, Greenovation
Biotech and FGK Clinical Research, Horizon Pharma, Leadiant Biosciences, Mylan,
Pfizer, Protalix, Raptor, Recordati, Synageva BioPharma, Valerion Therapeutics,
and Vtesse.
Market
driver
- Unmet medical needs
- For a full, detailed list, view our report
Market
challenge
- Expensive treatment regimen for LSDs
- For a full, detailed list, view our report
Market
trend
- Regulatory assistance in emerging nations
- For a full, detailed list, view our report
Key
questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
Spanning over 104 pages “Global
Lysosomal Storage Diseases Market 2017 - 2021” report covers Executive
summary, Introduction, Scope of the report, Research Methodology, Market
landscape, Understanding LSDs, Pipeline, Market segmentation by therapy, Market
segmentation by geography, Decision framework, Drivers and challenges, Trends,
Vendor landscape, Key vendor analysis, Appendix.
Please visit this link for more details: http://mrr.cm/Uwr
For related reports please visit: Lysosomal Storage Market Research Reports
Find all Pharma
and Healthcare Reports at: https://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.